MedTrace Logo

Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis

NCT00889694 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-04-29

No results posted yet for this study

Summary

This study is a 12-week, randomized, placebo and positive drug controlled clinical trial to investigate whether tripterygium capsule is effective and safe in treating patients with ankylosing spondylitis. The investigators expect that the tripterygium capsule is more effective than placebo and has few adverse effects.

Conditions

  • Early Ankylosing Spondylitis

Interventions

DRUG

Tripterygium

Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.

DRUG

Sulfasalazine

Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.

DRUG

placebo

Placebo: 2 capsules per time, 3 times per day for 12 weeks.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-07-31
Completion
2009-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00889694 on ClinicalTrials.gov